PainChek's business progress and developments

PainChek (ASX:PCK) has announced key developments in its business operations, including a 10% increase in implemented licenses, reaching 68,136 by November 2024. The company has also initiated a government-funded project and commenced an international trial in Scotland.

Overview and future outlook for PainChek

PainChek is making strides in its mission to advance pain assessment and management solutions. With a notable 10% increase in license implementations, the company is enhancing its market presence in ANZ and the UK. PainChek's new project, funded by the Western Australian government, aims to develop an innovative app for non-verbal children with disabilities. The ongoing trial at the Royal Infirmary of Edinburgh is a pivotal step towards broader global integration. PainChek's focus remains on expanding into new markets, notably the USA, and addressing the infant pain assessment gap. With regulatory clearances in multiple countries, the company is poised for further growth, awaiting FDA approval in the US. PainChek is dedicated to revolutionizing pain management through technology, ensuring effective pain assessment for all, including individuals with dementia and those in home care settings.

Insights from PainChek's executive commentary

We are pleased with the progress we have made in our business operations, particularly in the ANZ and UK markets. Our new contract structures and training programs have been pivotal in achieving faster rollout and implementation. The government-funded project and international trial further demonstrate our commitment to expanding our impact globally.